Literature DB >> 20829738

Evaluation of choroidal endothelial cell proliferation after exposure to varying doses of proton beam radiation.

Kakarla V Chalam1, Sankarathi Balaiya, Robert S Malyappa, Wen Hsi, Vikram S Brar, Ravi K Murthy.   

Abstract

PURPOSE: Focal epiretinal radiation has emerged as a promising tool in the management of choroidal neovascularization associated with age-related macular degeneration. However, the dosages tested are not backed by cell culture studies used in the clinical setting empirically.
METHODS: Choroidal endothelial cells (RF6A) were maintained in a log scale and exposed to a single fraction of 2, 4, 8, and 12 cobalt gray-equivalent of proton radiation with an internal control. Cell viability was quantified using Vi-cell XR and neutral red assay at days 5, 9, and 12 after radiation. Mitochondrial viability using WST-1 and reactive oxygen species levels using dihydrorhodamine 123 were measured at similar intervals.
RESULTS: By using neutral red assay, on day 12, the percentages of viable cells compared with control were 100.1 ± 5.7%, 96.7 ± 23.3%, 27.6 ± 6.6%, and 19.5 ± 3% at radiation doses of 2, 4, 8, and 12 cobalt gray-equivalent, respectively (P < 0.001). Increase in reactive oxygen species levels correlated with the number of dead cells implicating reactive oxygen species as an intermediary molecule (r = 0.85-0.96).
CONCLUSION: Our study shows sensitivity of cultured choroidal endothelial cells to proton beam radiation at doses of 8 and 12 cobalt gray-equivalent in an in vitro model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20829738     DOI: 10.1097/IAE.0b013e3181dee621

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  1 in total

1.  Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD.

Authors:  Jay Chhablani; Rama Jager; Joshua Ong; Ryan Lohrenz; Russell J Hamilton; Baldassare Stea; Mary Drew; Gregg Kokame
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-17       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.